TRUSTED BY LEADING COMPANIES
Accelerating drug discovery through our single-cell technology
QuRIE-seq is our patented single-cell technology that enhances the drug discovery and development process.
It enables the decoding of cellular responses by simultaneously quantifying mRNA molecules, as well as hundreds of membrane proteins, intracellular proteins, and phosphoproteins.
The basis of QurieGen’s approach is our ability to “lock” biology to build timelapse maps of cellular responses.
QuRIE-seq is leveraged through research partnerships with pharma companies
QurieGen addresses a set pressuring problems affecting all pharma companies: drug discovery and development costs are at an all-time high while the R&D efficiency is at an all-time low. There is no sign that this trend is stopping or slowing down.
We add value at every stage of the drug discovery and development process
Discovery Phases
- Finding new drug targets and combinations.
- Selecting leads based on favourable cell response patterns.
Pre-Clinical Trials
- Providing a high-resolution, quantitative MoA plan.
- Early identification of unwanted toxicity and non-responsive cells.
Clinical
Trials
- View of the heterogeneity of cell response.
- Detection of resistant cells subsets and other reasons for failure.